Introduction

As an organization committed to finding better ways to detect, treat, and ultimately cure ovarian cancer, we believe that future advances in ovarian cancer research lie in the hands of researchers.  OCRF funds the best researchers and the most innovative projects. Since 1998, OCRF has awarded 59 leading medical centers 147 grants for ovarian cancer research: an investment totaling more than $33 million.  OCRF is the largest independent organization in the United States dedicated exclusively to funding ovarian cancer research-- and to finding a cure.

Our Scientific Advisory Committee designed four funding programs to advance research.  Please click on the links below for more detailed information and lists of grantees:

- Program Project Development Grant
- Liz Tilberis Scholars Program
- Ann Schreiber Ovarian Cancer Research Training Program of Excellence
- Individual Investigator Awards Program

Also read our interviews with members of our Scientific Advisory Committee and grantees.  New interviews are posted regularly, so check back often! 

- Dr. Gary Leiserowitz on the biggest challenge in ovarian cancer research
- Dr. Molly Brewer on ovarian cancer and stem cells
- Dr. Alpa Nick, GCF Ann Schreiber Award, on a "breathalyzer" test for ovarian cancer
- Dr. Jose Conejo-Garcia, Liz Tilberis Scholar
- Dr. Andrew Berchuck on genetics and ovarian cancer
- Dr. Barbara Goff on the ovarian cancer symptoms study
- Dr. Jonathan Berek on the Cooperative Ovarian Cancer Group for Immunotherapy (COGI)

What research issues would you like to read about?  Send an email to grants @ocrf.org and let us know.

 

Grant Applications

OCRF has already awarded grants for the 2009/2010 year.

For 2010/2011, we anticipate offering new Program Project Development grants, Liz Tilberis grants, and Program of Excellence grants in.  The RFPs will be released in April 2010, and the deadline will likely be August or September 2010.  

For all grant-related questions, please contact Sarah DeFeo at grants@ocrf.org or 212.268.1002.